Yup, have felt that way for long time. W/O FDA protocols being public he cannot go public on details (see silence). And, BTW I do also think the plan all along has been for Rett (others possible) to be poster child for new trials planning.
It may also be important to Anavex that with the new FDA rules patient and caregiver testimony could carry more weight than before raising prospects of approval without fully supportive data. A la what happened recently with the approval of Sarepta's Eteplersin for DMD.